@article {LIN6265, author = {PAI-MEI LIN and HUI-MING LEE and CHUNG-I HUANG and TZONG-SHYUAN TAI and JIAN-HAN CHEN and CHIH-I CHEN and YU-CHIEH SU}, title = {Synergistic Antiproliferative Effect of Ribociclib (LEE011) and 5-Fluorouracil on Human Colorectal Cancer}, volume = {40}, number = {11}, pages = {6265--6271}, year = {2020}, doi = {10.21873/anticanres.14647}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Colorectal cancer (CRC) is one of the most common malignant tumors in the world. This study aimed to investigate the anticancer effect of the combination treatment of Ribociclib (LEE011) and 5-Fluorouracil (5-FU) on CRC cells. Materials and Methods: HT-29 and SW480 cells were treated with LEE011, 5-FU, or the combination of LEE011 and 5-FU. Cell viability and cycle were investigated through 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay and flow cytometry. The expression of cell cycle-related proteins was determined through western blot. Results: The combined treatment of LEE011 with 5-FU synergistically reduced cell viability in HT-29 and SW480 cells. Specifically, it induced cell cycle arrest at the G1 phase, down-regulated the phosphorylation of retinoblastoma protein and the expression of p53. Conclusion: LEE011 exhibited potential as an effective therapeutic inhibitor for the combination treatment of CRC patients.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/40/11/6265}, eprint = {https://ar.iiarjournals.org/content/40/11/6265.full.pdf}, journal = {Anticancer Research} }